New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
14:37 EDTVRTXVertex makes 'procedural' change to cystic fibrosis studies, TheStreet reports
Vertex Pharmaceuticals swapped the primary and secondary endpoints of two phase III trials investigating its combination cystic fibrosis therapy, making the primary endpoint of both studies the absolute change in lung function, though the company said it considers the move as "more procedural" than anything else and that it "was not based on anything going on in the study or anything observed in the study," reported TheStreet's Adam Feuerstein. Reference Link
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
09:27 EDTVRTXVertex shares likely to advance further, says RBC Capital
Subscribe for More Information
September 9, 2014
11:47 EDTVRTXStocks with call strike movement; FSLR VRTX
First Solar (FSLR) March 80 call option implied volatility increased 2% to 42, Vertex (VRTX) January 105 call option implied volatility increased 6% to 41 according to IVolatility.
September 8, 2014
11:05 EDTVRTXOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
September 5, 2014
10:05 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:41 EDTVRTXVertex upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Vertex Pharmaceuticals to Buy saying it sees a 90% probability of approval for the company's VX-809/Kalydeco combo for cystic fibrosis and a higher likelihood of M&A following the positive Phase 3 data in June. Goldman raised its price target for shares to $131 from $109.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use